BCAB
BioAtla, Inc.NASDAQHealthcare$5.65-13.34%ClosedMarket Cap: $6.6M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.18
P/S
3.32
EV/EBITDA
-0.10
DCF Value
$-5.01
FCF Yield
-512.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-2965.3%
Net Margin
-2980.3%
ROE
285.1%
ROA
-431.1%
ROIC
889.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $2.0M | 140.3% | $-9.3M | $-9.8M | $-0.16 | — |
| FY 2025 | $2.0M | 100.0% | $-59.3M | $-59.6M | $-1.01 | — |
| Q3 2025 | $0.00 | -Infinity% | $-13.8M | $-15.8M | $-0.27 | — |
| Q2 2025 | $0.00 | -Infinity% | $-18.6M | $-18.7M | $-0.32 | — |
| Q1 2025 | $0.00 | -Infinity% | $-17.6M | $-15.3M | $-0.26 | — |
| Q4 2024 | $0.00 | -Infinity% | $-16.2M | $-14.9M | $-0.30 | — |
| FY 2024 | $11.0M | 91.6% | $-73.9M | $-69.8M | $-1.44 | — |
| Q3 2024 | $11.0M | 97.9% | $-11.3M | $-10.6M | $-0.22 | — |
| Q2 2024 | $0.00 | -Infinity% | $-22.0M | $-21.1M | $-0.44 | — |
| Q1 2024 | $0.00 | -Infinity% | $-24.5M | $-23.2M | $-0.48 | — |
| Q4 2023 | $0.00 | -Infinity% | $-28.5M | $-26.9M | $-0.56 | — |
| FY 2023 | $0.00 | -Infinity% | $-129.7M | $-123.5M | $-2.58 | — |